NEW YORK, March 19 – Lynx Therapeutics has signed a collaboration with AstraZeneca to use its MegaType SNP detection technology to discover SNPs associated with asthma, the company said Tuesday.

Under the agreement, AstraZeneca will provide DNA samples from patients with asthma and from a control group, and Lynx of Menlo Park, Calif. will analyze the samples using the MegaType technology. MegaType involves Lynx's proprietary microbeads, which cleave to DNA fragments. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.